ImpedimedASX:IPD EBIT per Share is A$-0.01 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Impedimed ranks worse than 59.77% on this metric.
Impedimed's EBIT per Share for the
six
months ended in Dec. 2025 was A$-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 2.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 19.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 20.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Impedimed's EBIT per Share or its related term are showing as below:
ASX:IPD'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -27.1 Med: 14.2 Max: 42.4
Current: 2.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Impedimed was 42.40% per year. The lowest was -27.10% per year. And the median was 14.20% per year.
ASX:IPD's 3-Year EBIT Growth Rate is ranked worse than 59.77% of 691
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs ASX:IPD: 2.60
Impedimed's EBIT for the
six
months ended in Dec. 2025 was A$-10.40 Mil.
Impedimed (ASX:IPD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Impedimed EBIT per Share Related Terms
Impedimed EBIT per Share Historical Data
* Premium members only.
The historical data trend for Impedimed's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Impedimed (ASX:IPD) has a EBIT per Share of A$-0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Impedimed and its competitors. According to the industry distribution chart, Impedimed ranks #413 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 59.8%.
Is Impedimed's EBIT per Share too high?
Impedimed's current EBIT per Share is A$-0.01. Based on the distribution chart, Impedimed ranks #413 out of 691 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Impedimed's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Impedimed ranks #413 out of 691 companies for EBIT per Share. This places Impedimed in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Impedimed and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impedimed's current EBIT per Share is A$-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 93.8% below its estimated fair value. The current EBIT per Share is A$-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current EBIT per Share is A$-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IPD has been successfully added to your 